Related Experiment Video

Updated: Mar 5, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Practical Review of Recognition and Management of Obesity and Lipohypertrophy in Human Immunodeficiency Virus

Jordan E Lake¹, Takara L Stanley², Caroline M Apovian^3,4

¹Department of Medicine, University of Texas Health Science Center at Houston.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America

|March 23, 2017

Abstract

Background:

Obesity and lipohypertrophy are common in treated human immunodeficiency virus (HIV) infection and contribute to morbidity and mortality among HIV-infected adults on antiretroviral therapy (ART).

Methods:

We present a consensus opinion on the diagnosis, clinical consequences, and treatment of excess adiposity in adults with treated HIV infection.

Results:

Obesity and lipohypertrophy commonly occur among HIV-infected adults on ART and may have overlapping pathophysiologies and/or synergistic metabolic consequences. Traditional, HIV-specific, and ART-specific risk factors all contribute. The metabolic and inflammatory consequences of excess adiposity are critical drivers of non-AIDS events in this population. Although promising treatment strategies exist, further research is needed to better understand the pathophysiology and optimal treatment of obesity and lipohypertrophy in the modern ART era.

Conclusions:

Both generalized obesity and lipohypertrophy are prevalent among HIV-infected persons on ART. Aggressive diagnosis and management are key to the prevention and treatment of end-organ disease in this population and critical to the present and future health of HIV-infected persons.

Keywords:

antiretroviral therapy.human immunodeficiency virus (HIV)lipohypertrophy obesity

More Related Videos

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

Related Concept Videos

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Sexually Transmitted Infections

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...

Keywords:

antiretroviral therapy.human immunodeficiency virus (HIV)lipohypertrophy obesity

Articles linked to this work by shared authors, journal, and citation graph.

Incretin-Based Therapies: A Testable Hypothesis Linking Incretin Signaling, Mitochondrial Redox, and OXPHOS Efficiency.

Obesity (Silver Spring, Md.)·2026

Residual late risk of severe adverse events in metabolic bariatric surgery patients after discharged emergency department visit.

The American journal of emergency medicine·2026

Standardized inpatient protein-sparing modified fast as a bridge to metabolic/bariatric surgery in high-risk acutely ill adults with severe obesity.

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery·2026

Fixed-dose, extended-release combination of naltrexone and bupropion reduces craving and body weight: A pooled post hoc analysis.

Obesity research & clinical practice·2026

A Remote Program for Navigator- and Pharmacist-Led Management of Obesity Medications in Adults: Rationale, Design, and Implementation.

Obesity science & practice·2026

Identifying Predictors of Weight-Related Outcomes With Fixed-Dose, Extended-Release Naltrexone and Bupropion Among Treatment-Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis.

Obesity science & practice·2026

See all related articles